Our Pricing

What Results Can You Expect With Mounjaro Treatment?

Published on: June 03, 2026

Understanding the mounjaro results uk timeline helps set realistic expectations for your weight loss journey. Clinical trials demonstrate that Mounjaro (tirzepatide) produces significant, sustained weight reduction when combined with lifestyle changes, with most UK patients seeing measurable results within the first month of treatment. At Cured Pharmacy, our UK prescribers assess your suitability and guide you through what to expect at each stage of your Mounjaro treatment.

Mounjaro Results UK Timeline: What Clinical Trials Show

The SURPASS clinical trial programme provides the most comprehensive data on Mounjaro results available to UK patients. In the pivotal SURPASS-1 trial, participants achieved an average weight reduction of 15.0% to 22.5% over 72 weeks, depending on the maintenance dose prescribed [1]. These results represent outcomes in adults with a body mass index of 27 kg/m² or greater, which aligns with MHRA licensing criteria for weight management use in the UK.

Weight loss with Mounjaro follows a predictable pattern across most patients. During weeks 1-4, you may lose 2-4% of your starting body weight as the medication begins reducing appetite and slowing gastric emptying [1]. Between weeks 8-20, weight loss typically accelerates as your dose is gradually increased to the optimal maintenance level. Maximum weight reduction usually occurs between weeks 52-72, with most patients maintaining their results when continuing treatment alongside dietary modifications [2].

Individual results vary based on starting weight, adherence to the prescribed dosing schedule, dietary changes, and physical activity levels. Your UK prescriber will monitor your progress and adjust your treatment plan accordingly, ensuring you receive the dose that balances efficacy with tolerability.

How Mounjaro Produces Weight Loss Results

Mounjaro contains tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for weight management [1]. This dual mechanism distinguishes it from single-pathway treatments like semaglutide. By activating both GIP and GLP-1 receptors, tirzepatide enhances insulin secretion when blood glucose is elevated, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways [3].

The appetite suppression effect is particularly pronounced with Mounjaro. Clinical trial participants reported significant reductions in hunger and food cravings within the first two weeks of treatment [1]. This early effect helps patients adhere to reduced-calorie eating patterns, which amplifies the metabolic benefits of the medication itself.

Unlike older weight loss medications that work through a single mechanism, Mounjaro's dual action addresses multiple pathways involved in energy balance and glucose regulation. This comprehensive approach explains why clinical trials demonstrated superior weight loss compared to placebo and active comparators [2].

Dose Escalation and Results

Mounjaro treatment begins with a 2.5 mg once-weekly injection for the first four weeks. Your UK prescriber will then increase your dose gradually—typically to 5 mg, then 7.5 mg, 10 mg, 12.5 mg, or 15 mg—based on your response and tolerability [1]. This gradual escalation minimises gastrointestinal side effects whilst allowing your body to adapt to the medication's effects. Higher maintenance doses generally produce greater weight loss, but your prescriber will identify the optimal dose that balances efficacy with side effect management.

Mounjaro Results UK: Real Patient Outcomes

In the SURPASS-3 trial, which compared Mounjaro directly against insulin degludec in adults with type 2 diabetes, participants on the 15 mg maintenance dose achieved an average weight reduction of 13.9 kg (approximately 2 stone 3 pounds) over 52 weeks [2]. Those on the 10 mg dose lost an average of 11.2 kg (1 stone 10 pounds), whilst the 5 mg dose produced an average loss of 8.5 kg (1 stone 5 pounds) [2].

The SURMOUNT-1 trial, which specifically enrolled participants without diabetes, demonstrated even more pronounced results. Adults receiving Mounjaro 15 mg lost an average of 22.5% of their body weight over 72 weeks—equivalent to approximately 24 kg (3 stone 10 pounds) for someone starting at 105 kg [4]. Importantly, 91% of participants on the highest dose achieved at least 5% weight loss, and 57% achieved at least 20% weight loss [4].

UK patients starting Mounjaro through Cured Pharmacy receive the same pharmaceutical-grade medication used in these clinical trials. All Mounjaro supplied is UK-licensed and sourced through legitimate pharmaceutical supply chains, ensuring you receive genuine tirzepatide at the prescribed strength. Results you achieve will depend on adherence to your prescribed dose, dietary modifications, and individual metabolic factors, but clinical trial data provides realistic benchmarks for what is achievable under medical supervision.

Comparing Mounjaro Results to Other Weight Loss Treatments

Head-to-head clinical data helps contextualise Mounjaro's efficacy relative to other prescription weight loss medications available in the UK. In the SURPASS-2 trial, tirzepatide was compared directly against semaglutide 1 mg (the active ingredient in Wegovy, though at a lower dose than the weight management formulation). Participants on Mounjaro 15 mg achieved significantly greater weight loss—an average of 13.1 kg versus 7.9 kg with semaglutide 1 mg over 40 weeks [5].

Compared to liraglutide (Saxenda), another GLP-1 receptor agonist requiring daily injections, Mounjaro demonstrates superior weight loss outcomes. The SCALE trial programme for liraglutide 3.0 mg showed an average weight reduction of 8.4 kg over 56 weeks [6], whilst Mounjaro participants achieved greater reductions in shorter timeframes at equivalent trial stages [1][2].

Orlistat-based treatments like Xenical and Alli work through a different mechanism—blocking fat absorption in the digestive system—and typically produce more modest results. Clinical trials of orlistat 120 mg showed an average weight loss of 2.9 kg beyond placebo over one year [7], which is substantially less than injectable GLP-1 or dual GIP/GLP-1 treatments. Your UK prescriber will recommend the most appropriate treatment based on your medical history, weight loss goals, and tolerance for different administration methods.

Which Treatment Produces the Best Results?

Clinical trial data suggests Mounjaro produces the greatest average weight loss among currently licensed treatments in the UK, but individual responses vary. Some patients achieve excellent results with semaglutide-based treatments like Wegovy, whilst others may prefer the convenience and lower cost of oral medications like orlistat. Your UK prescriber at Cured Pharmacy will assess your medical history, current medications, weight loss targets, and personal preferences to recommend the treatment most likely to produce optimal results for your specific circumstances.

Maintaining Your Mounjaro Results Long-Term

Clinical trial extension studies demonstrate that weight loss achieved with Mounjaro can be sustained with continued treatment. In SURMOUNT-1, participants who continued tirzepatide maintained their weight reduction through 72 weeks, with minimal regain during the maintenance phase [4]. However, discontinuation of treatment typically results in gradual weight regain, as the appetite-suppressing and metabolic effects of the medication diminish.

Long-term success with Mounjaro requires integrating the medication into a broader weight management strategy. This includes adopting sustainable dietary changes—such as portion control, increased protein intake, and reduced consumption of energy-dense processed foods—alongside regular physical activity. UK clinical guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for weight maintenance, which complements the metabolic benefits of tirzepatide [8].

Your UK prescriber will schedule regular follow-up assessments to monitor your progress, adjust your dose if needed, and provide guidance on lifestyle modifications that support long-term weight maintenance. At Cured Pharmacy, ongoing prescriptions are subject to clinical review to ensure treatment remains appropriate and effective for your individual circumstances.

What Happens If You Stop Taking Mounjaro?

Clinical data shows that most patients experience gradual weight regain after discontinuing Mounjaro, typically regaining approximately 50-80% of lost weight within one year of stopping treatment [4]. This reflects the underlying biological drivers of obesity, which are not permanently altered by medication alone. Some patients choose to continue Mounjaro long-term to maintain their results, whilst others use it as a tool to achieve initial weight loss before transitioning to lifestyle-based maintenance strategies. Your UK prescriber will discuss the most appropriate treatment duration based on your individual goals and response to therapy.

Starting Mounjaro Treatment at Cured Pharmacy

Mounjaro is a prescription-only medication in the UK, requiring clinical assessment by a registered prescriber before it can be dispensed. At Cured Pharmacy, the process begins with a free online consultation that takes under three minutes to complete. You'll provide information about your medical history, current medications, weight loss goals, and any previous weight management attempts. This information is reviewed by our UK-registered clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

If Mounjaro is deemed clinically appropriate for you, your prescription will be issued and your medication dispatched in discreet packaging for next-day delivery across the UK. Mounjaro is priced at £124.99 at Cured Pharmacy, with transparent upfront pricing displayed before you complete your consultation—no hidden fees or surprise charges. All Mounjaro supplied is genuine UK-licensed medication sourced through legitimate pharmaceutical channels, ensuring you receive the same quality product used in clinical trials.

Your initial prescription will typically start with the 2.5 mg dose for the first month, with follow-up consultations scheduled to assess your response and adjust your dose according to the licensed escalation schedule. Our clinical team remains available throughout your treatment to address questions, monitor side effects, and optimise your dosing regimen. You can contact Cured Pharmacy at (+44) 116 4646009 or through our online portal for clinical support at any stage of your treatment journey.

Scientific References

1. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
2. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583-598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
3. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102 [accessed 13 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-218. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503-515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
6. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11-22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
7. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155-161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
8. National Institute for Health and Care Excellence. (2023). Weight management: lifestyle services for overweight or obese adults. NICE guideline [PH53]. https://www.nice.org.uk/guidance/ph53 [accessed 13 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to prescribed treatment, dietary modifications, and lifestyle factors.